The aim of this study is to evaluate the efficacy and safety of I10E (LFB 10% ready-to-use
liquid human intravenous immunoglobulin) compared to Kiovig® for the maintenance treatment of
MMN in a randomized, double-blind, active comparator-controlled, cross-over trial.
Phase:
Phase 3
Details
Lead Sponsor:
Laboratoire français de Fractionnement et de Biotechnologies
Collaborator:
TFS Trial Form Support
Treatments:
Antibodies Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous